Momenta Pharmaceuticals, Inc. (MNTA) Release: First Patient Dosed With M402 in Phase 1/2 Clinical Trial in Metastatic Pancreatic Cancer  
7/2/2012 9:28:19 AM

CAMBRIDGE, Mass., July 2, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that dosing has begun in the Phase 1/2 proof-of-concept clinical trial of M402 in combination with gemcitabine in patients with advanced metastatic pancreatic cancer.